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Background: The main barriers to non-viral gene delivery include cellular and nuclear 
membranes. As such, the aim of this study was to develop a type of vector that can target cells 
through receptor-mediated pathways and by using nuclear localization signal (NLS) to increase 
the nuclear uptake of genetic materials.
Methods: A dexamethasone (Dexa)-conjugated lipid was synthesized as the material of the 
solid lipid nanoparticles (SLNs), and transferrin (Tf) was linked onto polyethylene glycol-
phosphatidylethanolamine (PEG-PE) to obtain Tf-PEG-PE ligands for the surface modification 
of the carriers. The in vitro transfection efficiency of the novel modified vectors was evaluated in 
human hepatoma carcinoma cell lines, and in vivo effects were observed in an animal model.
Results: Tf-PEG-PE modified SLNs/enhanced green fluorescence protein plasmid (pEGFP) 
had a particle size of 222 nm and a gene loading quantity of 90%. Tf-PEG-PE-modified SLNs/
pEGFP (Tf-SLNs/pEGFP) displayed remarkably higher transfection efficiency than non-modified 
SLNs/pEGFP and the vectors not containing Dexa, both in vitro and in vivo.
Conclusion: It can be concluded that Tf and Dexa could function as an excellent active targeting 
ligand to improve the cell targeting and nuclear targeting ability of the carriers, and the resulting 
nanomedicine could be a promising active targeting drug/gene delivery system.
Keywords: gene delivery, active targeting, transferrin-PEG-PE, dexamethasone conjugated 
lipid, nuclear localization
Introduction
The success of gene-loaded nanomedicine requires efficient targeted gene delivery 
systems. Non-viral gene delivery systems, such as liposomes,1 polymers,2 and solid 
lipid nanoparticles (SLNs),3 have been developed as alternatives to viral gene delivery 
systems, in order to overcome the disadvantages of viral vectors.4 Although non-viral 
carriers have advantages, such as being less toxic, low immunogenic, and easy to modify, 
low transfection efficiency compared to viral carriers limit their applications.5 Therefore, 
diverse approaches have been applied to potentiate non-viral gene delivery vectors.6
The main barriers to non-viral gene delivery include cellular and nuclear 
membranes.6,7 Cellular uptake could be facilitated through receptor-mediated path-
ways by surface modification of specific ligands to carriers.8,9 In addition, nuclear 
localization signals (NLS) have been used to increase nuclear uptake of genetic 
materials.10,11 The glucocorticoid receptor (GR) is a nuclear receptor;12 when it binds 
to the ligand, the receptor–ligand complex translocates from the cytoplasm to the 
nucleus.13 It has been reported that glucocorticoid receptors can dilate nuclear pores up 
to 60 nm during the translocation process, which is favorable for the translocation of 
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DNA into the nucleus.14 Therefore, the transport of genes into 
the nucleus may be enhanced by conjugating glucocorticoids 
to carriers. Dexamethasone (Dexa), an effective, synthetic 
glucocorticoid, could bind to the glucocorticoid receptor 
after cellular entry and translocate the complexes into the 
nucleus.15–20 The results of these studies have confirmed that 
Dexa-conjugated vector/DNA complexes could be efficiently 
delivered into the nucleus with the glucocorticoid receptor, 
resulting in increased transgene expression.
Recently, much attention has been given to the use of 
cationic SLNs as gene carriers that might offer a number of 
technological advantages, including better storage stability 
in comparison to liposomes, the possibility of steam steriliza-
tion and lyophilization, large scale production with qualified 
production lines, and the use of substances that are generally 
accepted as safe.21–26 The cationic lipids used for the prepara-
tion of lipid nanoparticles include cetyltrimethylammonium 
bromide (CTAB),27 N-[1-(2,3-dioleyloxy) propyl]-N,N,N- 
tri-methylammonium chloride (DOTMA),28 and dim-
ethyldioctadecylammonium bromide (DDAB).29 However, 
toxicity is still an obstacle to the use of cationic lipids. Some 
researchers have indicated that cationic lipids with ester 
bonds are more biodegradable and, therefore, are associated 
with less cytotoxicity.23,30,31 Tang and colleagues demon-
strated that 6-lauroxyhexyl ornithinate (LHON) with one tail 
was more efficient and had lower cytotoxicity. Therefore, 
LHON was used as the cationic lipid in this study.
Polyethylene glycol-phosphatidylethanolamine (PEG-
PE) conjugates with various PEG lengths, and termi-
nal-targeted moieties can provide extremely stable, 
long-circulating, and actively targeted nanocarriers, which 
spontaneously accumulate at specific sites.32,33 These types 
of ligands also have been used previously by our group for 
surface modification of vehicles to achieve targeted gene 
delivery.1,34 Transferrin (Tf), an iron-binding glycoprotein, is 
a well-studied ligand for delivering anticancer drugs/genes, 
due to the increased number of Tf receptors found on tumor 
cells compared to normal cells.35,36 This receptor-mediated 
endocytosis could facilitate the delivery of drugs/genes 
into cells.37–39 In this study, Tf was linked onto PEG-PE to 
form Tf-PEG-PE as ligands for the surface modification 
of nanocarriers.
In the present study, a Dexa-conjugated LHON 
  (Dexa-LHON) was synthesized for the enhancement of 
nuclear localization of a gene. Enhanced green fluores-
cence protein plasmid (pEGFP) was used as the model 
gene. After the preparation of gene-loaded cationic SLNs 
(SLNs/pEGFP), novel Tf-PEG-PE was synthesized and 
modified onto the surface of the SLNs/pEGFP. The in 
vitro   transfection efficiency of the novel modified vectors 
was evaluated in human hepatoma carcinoma cell lines 
(HepG2 cells), and in vivo effects were observed in mice 
bearing human HepG2 cells model. Unmodified SLNs/
pEGFP, modified SLNs not containing Dexa (Tf-non-Dexa-
SLNs/pEGFP), and unmodified non-Dexa-SLNs/pEGFP 
were used as controls.
Materials and methods
Materials
Stearic acid, L-α-phosphatidylethanolamine  (PE),   
2- iminothiolane (Traut’s Reagent), Human Tf (iron-free), and 
(3-[4,5-dimehyl-2-thiazolyl]-2,5-diphenyl-2H-tetrazolium 
bromide (MTT) were purchased from Sigma-Aldrich Co, 
Ltd (St Louis, MO). Injectable soya lecithin was obtained 
from Shanghai Taiwei Pharmaceutical Co, Ltd (China). 
Dexamethasone-21- mesylate was purchased from Steral-
oids Inc. LHON was synthesized according to a previous 
procedure.30 Maleimide-PEG2000-COOH was purchased from 
Shanghai Yare Biotech Inc, (Shanghai, China). pEGFP-N1 
was provided by Shandong University (Shandong, China). 
Quant-iT™ PicoGreen® dsDNA quantitation reagent was 
obtained from Invitrogen by Life Technologies (Carlsbad, 
CA). HepG2 cells were obtained from the American type 
culture collection (Manassas, VA). All other chemicals were 
of analytical grade or higher.
Animals
BALB/c mice (4–6 weeks old, 18–22 g) were purchased 
from the Medical Animal Test Center of Shandong Province 
and housed under standard laboratory conditions. All animal 
experiments complied with the requirements of the National 
Act on the Use of Experimental Animals (People’s Republic 
of China).
Synthesis of Dexa-LHON and Tf-PEG-PE
The Dexa–LHON conjugation reaction was performed   
using the method reported previously, with some modifica-
tion.6 The synthesis scheme is depicted in Figure 1. Briefly, 
Dexa coupling to LHON was performed with 2 equivalent of 
Traut’s reagent, and 2 equivalent of dexamethasone mesylate 
in anhydrous DMSO for 6 hours at room temperature (RT). 
The same volume of water was added to the reaction mixture, 
and it was dialyzed against pure water and filtered through a 
0.45 µm, syringe-type filter, to remove insoluble impurities. 
Then, the product was obtained after freeze-drying, yielding 
a white, crystalline powder.
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Figure 1 General reaction scheme for synthesis of Dexa-LHON.
Abbreviations: Dexa, Dexamethasone; LHON, 6-lauroxyhexyl ornithinate.
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Figure 2 General reaction scheme for synthesis of Tf-PEG-PE.
Abbreviations: DMSO, dimethylsulfoxide; PEG, polyethylene glycol; PE, L-α-phosphatidylethanolamine; TEA, triethylamine; Tf, transferrin.
Tf-PEG-PE ligands were synthesized as described 
in Figure 2. Maleimide-PEG2000-COOH (100 mg) was 
dissolved with dimethyl sulfoxide (DMSO) and stirred with 
PE (36 mg) as a mixture. 1-[3-(dimethylamino)propyl]-   
3-ethylcarbodiimide (EDC ⋅ HCl) (72 mg) and triethylamine 
(TEA, 1 equivalent of EDC ⋅ HCl) were dissolved in DMSO, 
added, dropwise into the mixture in an ice bath, and stirred 
for 36 hours, to produce Maleimide-PEG-CO-NH-PE. Tf 
was first modified with 1 equivalent of Traut’s reagent to 
complete thiolation of Tf.40 The thiolated Tf was then added 
to the Maleimide-PEG2000-COOH solution, and the mixture 
was incubated for 2 hours at room temperature, with gentle 
stirring. The product was dialyzed against Milli-Q water for 
24 hours to form Tf-PEG-PE solution. The mixture was cen-
trifuged at 10,000 g for 30 min at 4°C, and then resuspended 
in PBS (pH 7.4).
Preparation of cationic SLNs/pEGFP
SLNs were prepared following the nanoprecipitation 
method (solvent displacement technique), as described 
previously (Figure 3).2,34 Stearic acid (50 mg) and injectable 
soya lecithin (30 mg) were accurately weighted and dis-
solved in 10 mL acetone. The organic phase was added, 
dropwise, into the 0.1% Dexa-LHON solution, which 
was being stirred at 600 rpm at room temperature. When 
complete evaporation of the organic solvent occurred, the 
redundant stabilizers were separated by ultracentrifugation 
at 1000 g, 4°C, for 20 min. The pellet was vortexed and 
resuspended in Milli-Q water, washed three times, filtered 
through a 0.45 µm membrane, and adjusted to pH 7.0 ± 0.1 
with sodium hydroxide. The obtained SLN suspensions were 
stored at 2°C–8°C. Non-Dexa-SLNs were prepared in the 
same manner, but using LHON without Dexa.
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Figure 3 Preparation of Tf-PEG-PE-modified SLNs/pEGFP.
Abbreviations: SLNs, solid lipid nanoparticles; pEGFP, enhanced green fluorescence protein plasmid; Tf, transferrin; PEG, polyethylene glycol; PE, L-α-phosphatidylethanolamine.
SLNs/pEGFP (non-Dexa-SLNs/pEGFP) complexes were 
prepared by incubating the SLNs (non-Dexa-SLNs) with 
pEGFP. Briefly, pEGFP was mixed with SLNs by vortex-
ing the particles with a 1 mg/mL solution of pEGFP for 
20 seconds. Incubation of the mixture for 20 minutes at RT 
facilitated the formation of SLNs/pEGFP (non-Dexa-SLNs/
pEGFP).
Modification of SLNs/pEGFP  
with Tf-PEG-PE
The Tf-PEG-PE ligands were dissolved in 5 mL of PBS 
(pH 7.4). Then, the solution was added, dropwise, to 20 mL 
of SLNs/pEGFP complexes that was stirred at 600 rpm at 
RT, leading to the immediate modification. Subsequently, 
free Tf-PEG-PE was removed from modified SLNs/pEGFP 
by gel chromatography, using a Sephadex® G-50 column. 
The obtained complexes were resuspended in Milli-Q 
water, washed three times, and filtered through a 0.80 µm 
pore size membrane, to obtain Tf-PEG-PE-SLNs/pEGFP 
(Tf-SLNs/pEGFP) (Figure 3). During this procedure, Tf-
PEG-PE ligands were continuously coated onto the surface 
of the SLNs/DNA, which would cause the decrease of zeta 
potential. To optimize the modification ratio, Tf-PEG-PE 
ligands dissolved in PBS were designed at different weight 
ratios to the SLNs (w/w), and the zeta potential of the com-
plexes was determined. Non-Dexa-SLNs/pEGFP were also 
modified per the above-mentioned method to form Tf-non-
Dexa-SLNs/pEGFP.
Characterization of Tf-SLNs/pEGFP
Size, size distribution, and zeta potential
The mean particle size, polydispersity index (PDI), and 
zeta potential of SLNs, SLNs/pEGFP, and Tf-SLNs/pEGFP 
were analyzed by photon correlation spectroscopy (PCS), 
with a Zetasizer 3000 (Malvern Instruments, Malvern, 
  England). The average particle size was expressed as 
  volume mean diameter, and the reported value was repre-
sented as mean ± SD (n = 3).
Gene loading capacity: PicoGreen® fluorometry assay
During the modification procedure, Tf-PEG-PE ligands were 
coated onto the SLNs/pEGFP carriers, due to the electric 
charge and lipophilic interaction. PicoGreen fluorometry 
assay was used to determine the appropriate modification 
rate of Tf-PEG-PE ligands and to quantitate the amount of 
pEGFP carried by the optimum modified SLNs.1 Different 
ratios of Tf-PEG-PE to SLNs/pEGFP (from 2% to 50%, w/w) 
were used to prepare Tf-SLNs/pEGFP complexes, and the 
pEGFP was isolated from Tf-SLNs/pEGFP by centrifuga-
tion at 1000 g, 4°C, for 30 minutes. The concentration of 
pEGFP was determined by fluorescence, comparing with the 
supernatant from blank SLNs. The amount of pEGFP loaded 
into the SLNs was calculated according to the linear cali-
bration curve of pEGFP: gene loading quantity (%) = (total 
amount of pEGFP – amount of free pEGFP)/total amount 
of DNA × 100.
In vitro release of Tf-SLNs/pEGFP
The in vitro release studies of SLNs/pEGFP and Tf-SLNs/
pEGFP were performed in PBS (pH 7.4).23 Aliquots of com-
plexes were suspended in 1 mL of PBS, in Eppendorf® tubes, 
and vortexed for 30 seconds. The tubes were then placed in 
a 37°C shaking water bath (100 rpm). Separate tubes were 
used for different data points. At predetermined time inter-
vals, the suspensions were centrifuged (1000 g, 30 minutes), 
and the amount of DNA released in the supernatant was 
analyzed by PicoGreen assay (mentioned in Section 2.6.2). 
Background readings were obtained using the supernatants 
from the blank SLNs.
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In vitro cytotoxicity evaluation
To examine cytotoxicity, HepG2 cells were seeded in 96-well 
plates at 8 × 103 cells/well and incubated for 24 hours, to allow 
cell attachment.41 The cells were   incubated with SLNs/pEGFP 
and Tf-SLNs/pEGFP complexes at various concentrations (10, 
20, 50, 100, and 200 µg/mL) for 48 hours at 37°C and 5% 
CO2 atmosphere, respectively.   Lipofectamine™ 2000 (Lipo) 
was used as a positive control, according to the manufacturer’s 
procedures. Cells without incubation were used as a negative 
control. Cellular viability was assessed using Cell Counting Kit-8 
(CCK-8; Dojindo Molecular Technologies, Inc., Gaithersburg, 
MD), according to the manufacturer’s procedures; the absorbance 
at 450 nm was measured using a microplate reader (Model 680; 
BIO-RAD, USA). Cells   without the addition of CCK-8 were used 
as a blank to calibrate the spectrophotometer to zero   absorbance. 
The relative cell viability (%) was calculated as:
  (Abssample − Absblank)/(Abscontrol − Absblank) × 100.
In vitro transfection analysis
For transfection efficiency analysis, the HepG2 cells were 
seeded into 24-well plates at a density of 1 × 105 cells/well 
and transfected the next day at 80%–90% confluency. Prior to 
transfection, the media were replaced with 400 µl transfection 
media containing Tf-SLNs/pEGFP. Naked DNA, unmodified 
SLNs/pEGFP, non-Dexa-SLNs/pEGFP, and Tf-non-Dexa-
SLNs/pEGFP were used as controls. The original incubation 
medium was replaced with 1 mL of complete medium after 
incubation at 37°C, for 4 hours, under a 5% CO2 atmosphere. 
The cells were incubated and studied until 72 hours post-
transfection. To quantitate the transfection efficiency, the 
cells were washed with 1 mL of PBS (100 g, 4°C, for 5 min) 
and were detached with trypsin/EDTA. The supernatant was 
discarded and resuspended with 300 µl of PBS, mixed well, 
and added into the flow cytometry, to determine the amount 
of HepG2 cells that had been successfully transfected.
Tumor model preparation
Tumor-bearing mice were prepared by inoculating (s.c.) a 
suspension of HepG2 cells (2 × 106 cells) into the right arm-
pit of BALB/c mice.40,42 Briefly, the mice were acclimatized 
at a temperature of 25°C ± 2°C and a relative humidity of 
70% ± 5% under natural light/dark conditions for one week 
before dosing. Then, the mice were injected subcutaneously 
in the right armpit with HepG2 cells suspended in PBS. 
Tumors were permitted to reach 8–10 mm in diameter before 
initiation of the studies.
In vivo transfection studies
In vivo transfection activity of Tf-SLNs/pEGFP was evaluated 
against HepG2 solid tumors in mice. Five groups of tumor-bear-
ing mice (eight per group) were used. The mice were injected 
intravenously with naked DNA, SLNs/pEGFP, non-Dexa-SLNs/
pEGFP, Tf-non-Dexa-SLNs/pEGFP, and Tf-SLNs/pEGFP. The 
mice were then euthanized at 48 hours or 72 hours after injection, 
and the tumor tissue samples were removed.43 The tumor tissues 
were homogenized by pressing the samples through a 30 µm 
cell mesh with the plunger of a 10 mL syringe; erythrocyte lysis 
buffer was added during homogenization to lyse the red blood 
cells. The homogenates were washed three times with PBS con-
taining 0.5% bovine serum albumin and then filtered. The cells 
were obtained after centrifugation (4°C, 100 g, five minutes) and 
were seeded into 24-well plates in 1 mL of Dulbecco’s Modi-
fied Eagle’s Medium with 10% fetal bovine serum (FBS). The 
fluorescent cells were observed using an inversion fluorescence 
microscope, at which time pictures were taken for the record. 
After that, the cells were washed with 1 mL of PBS (100 g, 
4°C for 5 minutes) and were detached with trypsin/EDTA. The 
supernatant was discarded, resuspended with 300 µl of PBS, 
and added into the flow cytometry to quantitate the amount of 
HepG2 cells that were successfully transfected.
Statistical analysis
All studies were repeated three times, and all measure-
ments were carried out in triplicate. Results were reported 
as means ± standard deviation (SD). Statistical significance 
was analyzed using the Student’s t-test. Differences between 
experimental groups were considered significant when the 
P-value was less than 0.05 (P , 0.05).
Results
Structure confirmation of Dexa-LHON 
and Tf-PEG-PE
The structures of Dexa-LHON and Tf-PEG-PE were con-
firmed by 1H NMR spectroscopy. The 1H NMR (dimethyl 
sulfoxide-d6, 300 mHz) data of Dexa-LHON is presented, 
and each proton peak is identified, in Figure 4. The peak 
intensity ratio was calculated between the ethyl protons of 
LHON backbone and the two methyl protons at 13′ and 16′ 
position of the five-numbered Dexa ring (δ 0.7–1.1 ppm). 
From the 1H NMR calculations, it was observed that 2 mol of 
Dexa was conjugated per 1.2 mol of LHON. The production 
rate was around 80%.
The 1H NMR data of Tf-PEG-PE (dimethyl sulfoxide-
d6, 300 mHz) was δ 2.50 (CH2CO, OCH2CH2NHCO), 3.28 
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Figure 4 1H NMR spectroscopy of Dexa-LHON.
Abbreviations: Dexa, Dexamethasone; LHON, 6-lauroxyhexyl ornithinate.
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Figure 5 Optimization of the modification ratios of Tf-PEG-PE to SLNs/pEGFP.
Abbreviations:  Tf,  transferrin;  PEG,  polyethylene  glycol;  PE,  L-α-
phosphatidylethanolamine; SLNs, solid lipid nanoparticles; pEGFP, enhanced 
green fluorescence protein plasmid.
(CH2N), 3.36–3.48 (OCH2CH2), 3.65 (NHCO), and 6.08 
(NH). The production rate was around 75%.
Optimization of the modification ratio
Tf-PEG-PE ligands were continuously coated onto the surface of 
the SLNs/DNA. This procedure would mask the cationic surface 
charge SLNs/DNA complexes and cause the decrease of zeta 
potential. The best ratio of the ligands to the carriers was opti-
mized by measuring the change of Zeta potential. As illustrated 
in Figure 5, the optimized ratio of Tf-PEG-PE to SLNs/DNA was 
30%. This ratio was determined for further experiments.
Characterization of Tf-SLNs/pEGFP
Size, zeta potential, and gene-loading capacity
Mean particle size, polydispersity index (PDI), and zeta 
potential of SLNs, SLNs/pEGFP, and Tf-SLNs/pEGFP are 
characterized and summarized in Table 1.
In vitro release of Tf-SLNs/pEGFP
The in vitro release profiles of Tf-SLNs/pEGFP and 
unmodified SLNs/pEGFP are illustrated in Figure 6. 
Both the Tf-SLNs/pEGFP and unmodified SLNs/pEGFP 
reached over 80% gene release at the time point of 72 hours.
In vitro cytotoxicity evaluation
In vitro cytotoxicity of Tf-SLNs/pEGFP and SLNs/pEGFP 
was evaluated by CCK-8 in HepG2 cells at different 
  concentrations. The cell viabilities of the vectors over the 
studied concentration range (10∼200 µg/mL) were between 
80% and 100% compared with the controls (Figure 7).
In vitro transfection analysis
The in vitro transfection efficiencies of Tf-SLNs/pEGFP, naked 
DNA, unmodified SLNs/pEGFP, non-Dexa-SLNs/pEGFP, and 
Tf-non-Dexa-SLNs/pEGFP were evaluated in HepG2 cells 
after 72 hours of transfection (Figure 8). Tf-SLNs/pEGFP 
showed higher transfection efficiency than Tf-non-Dexa-
SLNs/pEGFP and unmodified SLNs/pEGFP at 48 and 
72 hours post-transfection (P , 0.05).
In vivo gene delivery
In vivo gene delivery activity of Tf-SLNs/pEGFP was 
evaluated against HepG2 solid tumors in mice. The in vivo 
transfection efficiencies of Tf-SLNs/pEGFP, naked DNA, 
unmodified SLNs/pEGFP, non-Dexa-SLNs/pEGFP, and Tf-
non-Dexa-SLNs/pEGFP were observed and are shown in Fig-
ure 9. Tf-SLNs/pEGFP had a higher transfection efficiency at 
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Table 1 Particle size, zeta potential, and gene loading quantity of different vectors
Characteristics/  
samples
Mean particle  
size (nm)
Polydispersity  
index (PDI)
Zeta potential  
(mV)
Gene loading   
quantity (%)
SLNs 117.6 ± 3.5 0.13 ± 0.03 +42.5 ± 2.1 0
SLNs/pEGFP 178.1 ± 3.9 0.18 ± 0.02 +30.4 ± 2.8 91
Tf-SLNs/pEGFP 221.8 ± 5.8 0.14 ± 0.02 +18.9 ± 1.9 90
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different time intervals than the other vectors. Flow cytometry 
was applied to future quantitate the cells that were success-
fully transfected. As shown in Figure 10, Tf-SLNs/pEGFP 
displayed remarkably higher transfection efficiency than 
SLNs/pEGFP and the other vectors (P , 0.05).
Discussion
The aim of this study was to develop a type of vector that 
could overcome the main barriers to non-viral gene delivery, 
which include cellular and nuclear membranes. With a deep 
understanding of the gene delivery process, it is acknowl-
edged that efficient gene delivery requires multifunctional 
gene vectors that possess long circulation time, cellular or 
tissue targeting, and nuclear targeting.44 To overcome the 
barriers of cellular and nuclear membranes and achieve 
efficient gene therapy, a novel NLS conjugated cationic lipid 
(Dexa-LHON) was synthesized and used for the preparation 
of SLNs. A new, synthetic, Tf-containing ligand (Tf-PEG-PE) 
was used as a modifier, which was coated onto the nanocar-
rier’s surface after the preparation of gene-loaded cationic 
SLNs (SLNs/pEGFP).
The investigation began with the synthesis of a novel 
NLS-conjugated cationic lipid (Dexa-LHON). GR is 
a nuclear receptor, and when it binds to the ligand, the 
receptor–ligand complex translocates from the cytoplasm 
into the nucleus by means of the endogenous nuclear trans-
port machinery.45 In addition, the nuclear pore is dilated 
up to 60 nm during this process to facilitate the uptake of 
  transfected DNA into the nucleus.46 Moreover, glucocorti-
coids have a wide range of pharmacological effects, leading 
to pronounced anti-inflammatory and immunosuppressive 
effects and extensive clinical applications. Recent studies 
have proved that glucocorticoids encapsulated in long-
circulating liposomes exert strong inhibitory effects on 
tumor growth in a low dose and low frequency schedule after 
intravenous administration.47–49 The results of those studies 
have confirmed the enhancement of gene delivery by using 
steroid polymers. In the present study, a Dexa-conjugated 
lipid (Dexa-LHON) was synthesized for the enhancement of 
nuclear localization of genes.
Tf is a blood plasma protein for iron ion delivery; it is a 
glycoprotein that binds iron very tightly, but reversibly. When 
Tf loaded with iron encounters Tf receptors (TfR) on the 
surface of a cell, they bind, and are consequently transported 
into the cell. Tf is especially useful in targeting cancer cells, 
as many cancer cells over-express TfR on their surface.50 As 
such, Tf was used as the target moiety, which could bind to 
the TfR on the HepG2 cells. A series of PEG-containing 
ligands, commonly named PEG-phosphatidylethanolamine 
(PEG-PE) conjugates were reported on and used for the 
modification of various vehicles to make active-targeting 
nanocarriers spontaneously accumulate in specific sites.51 
Thus, PEG-PE was used at the anchor, and Tf-PEG-PE was 
used as the target ligand of the system.
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Figure 9 Fluorescent images of (A) naked DNA, (B) non-Dexa-SLNs/pEGFP, (C) unmodified SLNs/pEGFP, (D) Tf-non-Dexa-SLNs/pEGFP, and (E) Tf-SLNs/pEGFP 
at 24, 48, and 72 hours post-transfection.
Abbreviations: Tf, transferrin; SLNs, solid lipid nanoparticles; pEGFP, enhanced green fluorescence protein plasmid; Dexa, dexamethasone.
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Figure 8 In vitro transfection efficiencies of different systems in HepG2 cells after 
being transfected for 24, 48, and 72 hours.
Abbreviations: Tf, transferrin; SLNs, solid lipid nanoparticles; pEGFP, enhanced 
green fluorescence protein plasmid; Dexa, dexamethasone.
In recent years, much attention has been paid to the use 
of cationic SLNs as gene carriers, which may offer a num-
ber of technological advantages, including better storage 
  stability, relative ease to produce in large scale, and ability 
to be   modified.23 Our previous study focused on comparing 
two ways of modifying SLNs: pre-modification to form new 
modified vectors and post-modification after the gene was 
loaded.34 That investigation drew the conclusion that post-
modification of gene-loaded SLNs has the advantage over 
pre-modified ones. Therefore, the post-modify method was 
carried out in the present study. During the modification 
procedure, Tf-PEG-PE ligands were extensively coated 
onto the SLNs/DNA surface, which covered their original 
surface charge and caused the decrease in zeta potential. 
The optimization of ligand-to-carrier ratio was carried out by 
measuring the zeta potential. The optimum ratio was obtained 
at 30% (Tf-PEG-PE to SLNs/DNA, w/w) (Figure 5), and the 
optimum Tf-SLNs/pEGFP had a size of 221.8 nm and zeta 
potential of +18.9 mV (Table 1).
After the optimization of the modification procedure, 
the Tf-PEG-PE to SLNs/DNA ratio was determined as 30%, 
and it was used in further experiments. A PicoGreen fluo-
rometry assay was applied to determine the binding ability 
and in vitro release of Tf-SLNs/pEGFP and SLNs/pEGFP. 
The gene-loading efficiency of Tf-SLNs/pEGFP was 91%, 
which was not significantly different from SLNs/pEGFP 
(90%) (Table 1). The results demonstrated that binding 
the Tf-PEG-PE ligand did not detach the pEGFP from the 
  complexes. The in vitro release profile (Figure 6) of Tf-
SLNs/pEGFP showed a slightly slower release than SLNs/
pEGFP during the first 16 hours. This could be explained 
if the coating of the ligand hindered the release of DNA 
initially. After that, Tf-PEG-PE might detach from the vec-
tors, allowing the DNA to release more freely. At the end of 
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the release study, the total amount of DNA delivered by the 
two types of vehicles was nearly the same (over 80%).
In vitro cytotoxicity and transfection analysis were carried 
out in HepG2 cells. The cell viabilities of Tf-SLNs/pEGFP 
and SLNs/pEGFP over the studied concentration range 
were between 80% and 100%, compared with the controls 
(Figure 7). Tf-SLNs/pEGFP showed no higher cytotoxicity 
than SLNs/pEGFP at all concentrations. When compared 
with naked DNA and SLNs/pEGFP, Tf-SLNs/pEGFP had 
greater transfection efficiency at all time points (Figure 8). 
This may be explained by the receptor-mediated active tar-
geting mechanism. The Tf-SLNs/pEGFPs were more likely 
to bind to HepG2 cells via the TfR on the cells and thus, 
deliver DNA more easily into the cells. When compared with 
Tf-non-Dexa-SLNs/pEGFP (or non-Dexa-SLNs/pEGFP), Tf-
SLNs/pEGFP (or SLNs/pEGFP) with Dexa-conjugated lipid 
carrier had higher transfection efficiency at all time points. 
This could be evidence that the presence of Dexa facilitates 
the binding of the vectors to the glucocorticoid receptor after 
cellular entry and translocates the complexes into the nucleus, 
resulting in increased gene expression.
The gene delivery abilities of Tf-SLNs/pEGFP were tested 
further in animal models. In vivo gene delivery and expres-
sion studies were evaluated against HepG2 tumor-bearing 
mice. After intravenous injection, the rats were euthanized 
and the HepG2 cells were isolated at 24, 48, and 72 hours 
and analyzed. Tf-SLNs/pEGFP displayed remarkably higher 
transfection efficiency than unmodified SLNs/pEGFP and 
the other vectors without Dexa at all time points, as shown 
in Figures 9 and 10. These results were in agreement with 
the in vitro data and could further ensure the cell targeting 
and nuclear targeting ability of Tf-SLNs/pEGFP mediated 
by Tf, Dexa, and their receptors. These observations strongly 
support the active targeting ability of Tf-PEG-PE modified 
SLNs/pEGFP, and the resulting vectors would be very useful 
for in vivo gene delivery.
Conclusion
This study showed that glucocorticoid-mediated targeting 
could successfully enhance gene expression in cancer cells. It 
also demonstrated that having a targeting ligand, such as Tf-
PEG-PE, in SLNs formulations could significantly improve 
the transfection efficiency of the vector. Tf-SLNs/pEGFP 
had a remarkably higher transfection efficiency, both in vitro 
and in vivo, than unmodified SLNs/pEGFP and non-Dexa 
ones. It can be concluded, therefore, that Tf and Dexa can 
function as an excellent active targeting ligand to improve 
the cell and nuclear targeting ability of the carriers, and the 
resulting nanomedicine could be used as a promising active 
targeted drug/gene delivery system.
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